Your browser doesn't support javascript.
Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021.
Siller, Anita; Seekircher, Lisa; Wachter, Gregor A; Astl, Manfred; Tschiderer, Lena; Pfeifer, Bernhard; Gaber, Manfred; Schennach, Harald; Willeit, Peter.
  • Siller A; Central Institute for Blood Transfusion and Immunology, Tirol Kliniken GmbH, 6020 Innsbruck, Austria.
  • Seekircher L; Clinical Epidemiology Team, Medical University of Innsbruck, 6020 Innsbruck, Austria.
  • Wachter GA; Central Institute for Blood Transfusion and Immunology, Tirol Kliniken GmbH, 6020 Innsbruck, Austria.
  • Astl M; Central Institute for Blood Transfusion and Immunology, Tirol Kliniken GmbH, 6020 Innsbruck, Austria.
  • Tschiderer L; Clinical Epidemiology Team, Medical University of Innsbruck, 6020 Innsbruck, Austria.
  • Pfeifer B; Department of Clinical Epidemiology, Tyrolean Federal Institute for Integrated Care, Tirol Kliniken GmbH, 6020 Innsbruck, Austria.
  • Gaber M; Division for Healthcare Network and Telehealth, UMIT-Private University for Health Sciences, Medical Informatics and Technology GmbH, 6060 Hall, Austria.
  • Schennach H; Blood Donor Service Tyrol of the Austrian Red Cross, 6063 Rum, Austria.
  • Willeit P; Central Institute for Blood Transfusion and Immunology, Tirol Kliniken GmbH, 6020 Innsbruck, Austria.
Viruses ; 14(3)2022 03 09.
Article in English | MEDLINE | ID: covidwho-1732256
ABSTRACT
There is uncertainty about the seroprevalence of anti-SARS-CoV-2 antibodies in the general population of Austria and about the waning of antibodies over time. We conducted a seroepidemiological study between June 2020 and September 2021, enrolling blood donors aged 18-70 years across Tyrol, Austria (participation rate 84.0%). We analyzed serum samples for antibodies against the spike or the nucleocapsid proteins of SARS-CoV-2. We performed a total of 47,363 samples taken from 35,193 individuals (median age, 43.1 years (IQR 29.3-53.7); 45.3% women; 10.0% with prior SARS-CoV-2 infection). Seroprevalence increased from 3.4% (95% CI 2.8-4.2%) in June 2020 to 82.7% (95% CI 81.4-83.8%) in September 2021, largely due to vaccination. Anti-spike IgG seroprevalence was 99.6% (95% CI 99.4-99.7%) among fully vaccinated individuals, 90.4% (95% CI 88.8-91.7%) among unvaccinated individuals with prior infection and 11.5% (95% CI 10.8-12.3%) among unvaccinated individuals without known prior infection. Anti-spike IgG levels were reduced by 44.0% (95% CI 34.9-51.7%) at 5-6 months compared with 0-3 months after infection. In fully vaccinated individuals, they decreased by 31.7% (95% CI 29.4-33.9%) per month. In conclusion, seroprevalence in Tyrol increased to 82.7% in September 2021, with the bulk of seropositivity stemming from vaccination. Antibody levels substantially and gradually declined after vaccination or infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Donors / COVID-19 Topics: Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Year: 2022 Document Type: Article Affiliation country: V14030568

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Donors / COVID-19 Topics: Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Year: 2022 Document Type: Article Affiliation country: V14030568